Summary of 17 patients with grade 4 glioma, including response assessment and overall survival, in the dose cohort, and after the first cycle and extended monotherapy with CGA
| Patient ID | Dose cohort (mg/kg) | Primary diagnosis/pathology | Grade | Gender | Dosing C1D1 | First treatment cycle (days) | Assessment after first cycle | Extended CGA only | Death date | Days (from start of CGA to death)* |
|---|---|---|---|---|---|---|---|---|---|---|
| 0001 | 2 | GBM | 4 | Male | 2016/4/12 | 28 | SD | No | 2020/2/29 | 1419 |
| 0002 | 2 | GBM | 4 | Male | 2016/4/20 | 28 | PD | No | 2016/6/22 | 64 |
| 0003 | 2 | GBM | 4 | Female | 2016/6/7 | 28 | PD | No | 2017/1/22 | 230 |
| 0005 | 3 | GBM, containing oligodendroglioma | 4 | Female | 2016/7/28 | 28 | SD | Yes | NA | NA |
| 0006 | 3 | GBM | 4 | Male | 2016/8/11 | 28 | PD | No | 2017/2/15 | 189 |
| 0007 | 4 | Astrocytoma mixed with GBM | 4 | Male | 2016/9/23 | 28 | PD | No | 2017/5/2 | 222 |
| 0009 | 4 | GBM | 4 | Female | 2016/12/22 | 28 | PD | No | 2017/2/11 | 52 |
| 0010 | 5.5 | GBM | 4 | Female | 2017/2/10 | 27 | PD | Yes | 2018/12/5 | 664 |
| 0012 | 5.5 | Astrocytoma mixed with GBM | 4 | Male | 2017/2/24 | 28 | PD | No | 2017/6/28 | 125 |
| 0013 | 3 | Anaplastic astrocytoma mixed with GBM (right frontal) | 4 | Female | 2017/3/9 | 28 | PD | No | 2019/8/29 | 904 |
| 0019 | 3 | GBM with massive necrosis | 4 | Female | 2017/6/6 | 28 | SD | Yes | 2019/12/17 | 925 |
| 0021 | 4 | GBM (right frontal) | 4 | Male | 2017/6/22 | 28 | PD | No | 2017/9/21 | 92 |
| 0022 | 4 | GBM (right frontal) | 4 | Female | 2017/7/6 | 28 | PD | No | 2017/12/3 | 151 |
| 0023 | 4 | GBM (right thalamus) | 4 | Female | 2017/7/7 | 28 | SD | No | 2018/9/15 | 436 |
| 0024 | 4 | GBM | 4 | Female | 2017/7/10 | 28 | SD | Yes | 2017/11/13 | 127 |
| 0004 | 3 | Astrocytoma with mucus-like transformation | 4 | Male | 2016/7/27 | 28 | SD | Yes | 2018/5/10 | 653 |
| 0015 | 3 | Anaplastic astrocytoma with focal necrosis | 4 | Female | 2017/3/24 | 28 | SD | Yes | 2018/2/24 | 338 |
C1D1, cycle 1 day 1; NA, not applicable. *Including CGA monotherapy, and its combination with TMZ and other standard-of-care therapeutics after the first treatment cycle of CGA until the follow-up on February 11, 2022.